Prasun Mishra, PhD (Ex-Genentech, Ex-NCI/NIH) is a scientist turned entrepreneur currently leading the scientific, strategic and business aspects of Agility Pharmaceuticals (Agility), based in San Francisco Bay Area, CA. Agility is very promising company pioneering the artificial intelligence (AI)-driven pharmaceutical industry, as evident by key partnerships and recognition by scientific and tech community, including the Inaugural Silicon Valley Artificial Intelligence Team Award at Google Launchpad (2017). He is also founding president and CEO of American Association for Precision Medicine (AAPM), a professional organization dedicated to advancing the field of precision medicine. He has collectively over 16 years of solid record of performance in big pharma, government, academia, start-up & healthcare settings that spans multiple therapeutic areas, including oncology, inflammation, fibrosis and aging. He is best known for discovering the role for noncoding RNA in drug resistance and pharmacogenomics. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and mechanisms of action/resistance of both new and established drugs, which has facilitated development of rational drug combinations in the clinic.
While at Genentech, besides translational research, he participated in discovery project teams at various stages, from HTS assay development to early clinical development, providing/ interpreting data, gaining insights into target biology, drug design and optimization. He was also instrumental in identified a new transcript profiling platform and integrated genomics tools to support new target identifications/hit-to-lead efforts. He also developed and supported data analysis workflows for highly advanced technologies and tools for large-scale biology to ensure effective achievement of scientific/business objectives. He was also instrumental in establishing robotic automation (robotization) driven cell based phenotypic screening capabilities and hit to lead identification efforts within Genentech. He also led Genentech’s first full deck mammalian cell based phenotypic drug screen, hit triaging and hit to lead efforts to its successful completion. While at Genentech he contributed to a new target nomination proposal, established phenotypic screening capabilities and made critical go-no-go decisions for drugs/drug combinations. Moreover his research work at Genentech contributed to acquisition of a new precision oncology drug by Roche currently in Phase 1 clinical trials. He received his Ph.D. in Cellular and Molecular Pharmacology from Rutgers University with Highest Honors (a Dean’s Research Award, three Young Investigator Awards, as well as the Outstanding Thesis Research Award) and a post-doctoral training at the National Institutes of Health (NIH) (selected to become NIH-Tenure Track Investigator). Before establishing his laboratory at Genentech, he served as a PI at National Cancer Institute (NCI), NIH on two peer-reviewed NCI/NIH-funded intramural grants/awards focused on identifying and characterizing novel drugs/targets/drug combinations utilizing phenotypic/genetic screenings, hit-to-lead efforts, preclinical testing followed by clinical investigation.
In addition to his professional commitments, Dr. Mishra also gives back to his local biotech community by serving as an advisor to several companies in the San Francisco Bay Area to advance their R&D and funding strategy. He is well respected in the Bay Area life scientific and entrepreneur community. The companies that he has advised have collectively raised multi million dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Project Zygote and California Life Sciences Association, to help grow California’s life sciences innovation ecosystem. Moreover, discoveries lead by Dr. Mishra and his teams have contributed to the development of new and viable strategies of prevention, diagnosis and treatment of patients in the clinic.